From the Journals

Vitamin D deficiency linked to death, new study finds


 

FROM ANNALS OF INTERNAL MEDICINE

Mortality 36% higher in those deficient in vitamin D

The risk for mortality was a significant 36% higher for participants with 25-(OH)D 25 nmol/L compared with 50 nmol/L.

With the Mendelian randomization, there was an L-shaped association between genetically predicted 25-(OH)D level and all-cause mortality (P for nonlinearity < .001) and for mortality because of cancer and cardiovascular disease (P for nonlinearity ≤ .033).

Again, the strongest association with those outcomes and genetically predicted 25-(OH)D was found at levels below 25 nmol/L and a plateau was seen by 50 nmol/L.

Compared with a measured 25-(OH)D concentration of 50 nmol/L, investigators estimated that the genetically predicted odds of all-cause mortality would increase sixfold (odds ratio, 6.00) for participants at 10 nmol/L and by 25% (OR, 1.25) for those at 25 nmol/L.

And, compared with a measured 25-(OH)D concentration of 50 nmol/L, those with 10 nmol/L had genetically predicted odds ratios of 5.98 for cardiovascular mortality, 3.37 for cancer mortality, and 12.44 for respiratory mortality.

Comparing measured 25-(OH)D concentrations of 25 nmol/L versus 50 nmol/L, odds ratios for those outcomes were 1.25, 1.16, and 1.96 (95% confidence interval, 1.88-4.67), respectively. All were statistically significant.

Consistent results supportive of a causal effect of genetically predicted 25-(OH)D on all-cause mortality in those with low measured vitamin D concentrations were also found in a sensitivity analysis of 20,837 people of non-White ethnic origin.

The study was funded by the Australian National Health and Medical Research Council. Dr. Sutherland’s studentship is funded by an Australian Research Training Program Scholarship.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Presence of community health workers linked with better results in patients with T2D
MDedge Family Medicine
Type 1 diabetes cases poised to double worldwide by 2040
MDedge Family Medicine
The truth about the ‘happy hormone’: Why we shouldn’t mess with dopamine
MDedge Family Medicine
Cardiac biomarkers track with hormone therapy in transgender people
MDedge Family Medicine
It’s about location: PCOS symptoms differ depending where you live
MDedge Family Medicine
Diabetes becoming less potent risk factor for CVD events
MDedge Family Medicine
Don’t be afraid of weight gain with hyperthyroid treatment
MDedge Family Medicine
Few transgender teens discontinue hormones in young adulthood
MDedge Family Medicine
Goodbye ‘diabetes insipidus’, hello ‘AVP-D’ and ‘AVP-R’
MDedge Family Medicine
Stopping levothyroxine in subclinical hypothyroidism safe, feasible
MDedge Family Medicine